Cargando…
The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression
Depression is a global mental health concern, and personalized treatment approaches are needed to optimize its management. This study aimed to investigate the influence of the CYP2D6 and CYP1A2 gene polymorphisms on the efficacy of duloxetine in reducing depressive and anxiety symptoms. A sample of...
Autores principales: | Maciaszek, Julian, Pawłowski, Tomasz, Hadryś, Tomasz, Machowska, Marta, Wiela-Hojeńska, Anna, Misiak, Błażej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487921/ https://www.ncbi.nlm.nih.gov/pubmed/37686266 http://dx.doi.org/10.3390/ijms241713459 |
Ejemplares similares
-
Baseline depressive symptoms as predictors of efficacy and tolerability of the treatment with duloxetine: a network analysis approach
por: Maciaszek, Julian, et al.
Publicado: (2023) -
Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report
por: Beata, Sienkiewicz, et al.
Publicado: (2017) -
Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT
por: Sienkiewicz, Beata, et al.
Publicado: (2017) -
CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression
por: Han, Kyu-Man, et al.
Publicado: (2013) -
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice
por: Qin, Xuan, et al.
Publicado: (2023)